GlycoMimetics is a privately held clinical-stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs. Our Management Team consists of industry leaders with deep experience in the pharmaceutical/biotech industry. Since the company’s inception in 2003, GlycoMimetics has developed a robust, diversified product pipeline. The value of the approach has been validated by investments from prestigious investors like New Enterprise Associates (NEA) and the venture funds of Novartis and Genzyme, as well as by a major partnership with Pfizer. The company’s mission is to continue to advance its pipeline, providing hope for patients with sickle cell disease and various cancers.